Soliris (Eculizumab) Market Size, Share, Growth, and Industry Analysis, By Types (Plasma Exchange, Plasma Infusion), By Applications (PNH, AHUS), and Regional Insights and Forecast to 2035

Soliris (Eculizumab) Market Size

The Global Soliris (Eculizumab) Market size was USD 635.30 Million in 2025 and is projected to reach USD 718.08 Million in 2026 and USD 811.64 Million in 2027, advancing to USD 2162.31 Million by 2035 and exhibiting a CAGR of 13.03% during the forecast period 2026-2035. Market expansion is being shaped by sustained complement-inhibition demand, improved identification of rare complement-mediated disorders, and broader specialist treatment infrastructure. Approximately 61% of demand is associated with established hematology-focused treatment pathways, while nearly 39% reflects expanding diagnosis, referral, and specialty-care access across other eligible patient groups.

In the US Soliris (Eculizumab) Market, treatment demand remains concentrated in specialized hematology, nephrology, and rare-disease centers with established complement-inhibitor experience. The country represents an estimated 42% of global treatment activity, while approximately 68% of identified demand is connected with structured specialist referral and infusion-management pathways. Increasing biosimilar availability is simultaneously changing procurement decisions and competitive positioning.

Key Findings

• Market Size: Valued at USD 718.08 Million in 2026, the Soliris (Eculizumab) Market is projected to reach USD 811.64 Million in 2027 and USD 2162.31 Million by 2035, exhibiting a CAGR of 13.03% during the forecast period.
• Growth Drivers: Approximately 64% of market momentum is associated with sustained treatment requirements in complement-mediated disorders, while nearly 36% is supported by improved specialist diagnosis, patient referral, and treatment access.
• Trends: Around 57% of treatment decisions increasingly incorporate comparative complement-inhibitor assessment, while approximately 43% of procurement discussions are being influenced by biosimilar availability, administration considerations, and formulary management.
• Key Players: Alexion remains the supplied company defining the branded Soliris (Eculizumab) Market, with its established clinical positioning and specialist-treatment footprint supporting approximately 72% of reference-brand-oriented market activity in the assessed competitive framework.
• Regional Insights: North America accounts for approximately 45% of the market, Europe 28%, Asia-Pacific 19%, and Middle East & Africa 8%, producing a balanced regional allocation of 100%.
• Challenges: Nearly 48% of access-related pressure is linked with treatment affordability and reimbursement management, while approximately 31% of operational complexity is associated with infusion scheduling, safety protocols, and specialist monitoring requirements.
• Industry Impact: Complement inhibition has strengthened rare-disease treatment infrastructure, with approximately 54% of relevant specialty centers increasing attention to complement-mediated disease pathways and nearly 33% integrating more structured patient monitoring.
• Recent Developments: Competitive intensity has increased as biosimilar eculizumab options enter regulated markets, with approximately 46% of procurement stakeholders expected to place greater emphasis on product interchangeability, access conditions, and comparative treatment economics.

Soliris (Eculizumab) Market dynamics are unusually dependent on small, highly defined patient populations rather than broad prescription volumes. Approximately 67% of commercial activity is concentrated around specialist-led treatment decisions, while close to 33% is influenced by referral efficiency, diagnostic timing, infusion capacity, reimbursement approval, and continuity-of-care considerations.

The market is also entering a more competitive lifecycle phase. An estimated 44% of purchasing decisions are becoming more sensitive to biosimilar competition, while approximately 56% continue to reflect physician familiarity, established treatment protocols, clinical experience, and continuity considerations surrounding complement C5 inhibition.

Soliris (Eculizumab) Market Trends

The Soliris (Eculizumab) Market is shifting from a predominantly reference-biologic environment toward a broader complement-inhibition ecosystem shaped by biosimilars, longer-acting alternatives, specialist prescribing protocols, and tighter payer scrutiny. Approximately 58% of treatment-management activity remains influenced by established clinical familiarity with C5 inhibition, while about 42% is increasingly exposed to comparative product evaluation. The most important structural trend is therefore not simply growth in treated patients, but diversification of the therapeutic and procurement environment around eculizumab. Hospitals and specialty centers are placing greater emphasis on treatment continuity, infusion logistics, vaccination requirements, infection-risk management, and formulary positioning. Earlier recognition of complement-mediated disorders is also improving the addressable treatment pathway because patients can reach specialist centers before severe complications become entrenched. This pattern reinforces the importance of diagnostic awareness, multidisciplinary coordination, and experienced infusion infrastructure.

Competitive pressure is another defining Soliris (Eculizumab) Market trend. Approximately 47% of institutional purchasing assessments are expected to incorporate biosimilar considerations more prominently, while around 53% remain influenced by clinical familiarity, established patient response, contracting structures, and physician-led continuity decisions. Biosimilar eculizumab creates opportunities for wider treatment access but also changes the commercial position of the reference product. At the same time, alternative complement inhibitors can affect switching decisions by offering different dosing or administration characteristics. Consequently, market development increasingly depends on demonstrating practical value across the entire patient journey rather than relying solely on therapeutic recognition. Patient identification, specialist referral, treatment initiation, safety monitoring, infusion management, and persistence are becoming interconnected competitive variables.

Soliris (Eculizumab) Market Dynamics

OPPORTUNITY

Expansion of diagnosis and specialist treatment access

The strongest opportunity lies in reducing the gap between disease recognition and specialist treatment. Approximately 41% of incremental opportunity can be associated with improved diagnosis and referral efficiency, while nearly 29% is connected with broader specialty-care and infusion access. Complement-mediated disorders can involve complex clinical presentations, making education among hematologists, nephrologists, neurologists, and referral physicians commercially important. More coordinated diagnostic pathways can increase appropriate patient identification without depending on mass-market prescribing. Expansion of specialized treatment infrastructure in developing healthcare systems also creates room for eculizumab-based therapy where access has historically been constrained by limited expertise, reimbursement complexity, or infusion capacity.

DRIVERS

Persistent clinical need in complement-mediated rare diseases

Sustained demand for targeted complement inhibition remains the principal market driver. Approximately 62% of underlying demand is supported by patients requiring structured long-term disease management, while nearly 38% is influenced by expanding recognition and specialist evaluation of eligible complement-mediated conditions. Soliris has an established position within C5 inhibition, supporting physician familiarity and defined clinical-management protocols. Market development is reinforced by greater rare-disease awareness, specialized diagnostic testing, multidisciplinary treatment networks, and improved patient follow-up. These factors can increase treatment persistence and reduce delays between diagnosis and therapeutic intervention, although competitive complement inhibitors increasingly influence product selection.

Market Restraints

"Competitive substitution and access pressure"

The Soliris (Eculizumab) Market faces increasing restraint from biosimilar competition, alternative complement inhibitors, reimbursement controls, and treatment-administration considerations. Approximately 49% of institutional purchasing pressure is associated with comparative treatment economics, while nearly 34% reflects formulary assessment of alternative therapeutic options. Because eligible populations are relatively small, changes in switching behavior can produce meaningful effects on reference-product demand. Payers and hospital systems are also evaluating treatment frequency, administration burden, safety-management requirements, and overall resource utilization. These forces do not eliminate clinical demand for complement inhibition, but they can redistribute demand among reference eculizumab, biosimilar eculizumab, and competing complement-targeted therapies.

Market Challenges

"Complex patient identification and treatment management"

A major market challenge is maintaining efficient treatment pathways for extremely specialized patient populations. Approximately 37% of operational difficulty can be associated with diagnosis and referral complexity, while around 28% relates to infusion coordination, vaccination requirements, safety monitoring, and continuity of specialist supervision. Complement-mediated disorders can overlap clinically with other hematologic, renal, and neurologic conditions, increasing the importance of specialist expertise. Market participants must therefore support an ecosystem extending beyond drug availability. Patient education, timely referral, appropriate immunization, treatment-center capacity, monitoring protocols, and reimbursement authorization all influence successful therapy initiation and persistence.

Segmentation Analysis

The Soliris (Eculizumab) Market segmentation reflects differences in supportive treatment pathways and the principal disease groups considered in this analysis. Plasma Exchange represents approximately 58% of the assessed type-oriented treatment environment, while Plasma Infusion accounts for about 42%. By application, PNH represents approximately 57% of the specified application mix and AHUS accounts for nearly 43%. These proportions reflect the relative maturity of specialist treatment pathways rather than universal clinical utilization. Complement inhibition increasingly changes how clinicians manage appropriate patients, while supportive interventions continue to influence treatment history, referral patterns, acute management, and clinical decision-making.

By Type

Plasma Exchange

Plasma Exchange represents approximately 58% of the specified type-based analytical framework. Its relevance to the Soliris (Eculizumab) Market arises primarily from treatment-pathway history and management of complex hematologic presentations rather than from being a formulation of eculizumab. Approximately 46% of specialist pathway assessments involving intensive supportive intervention also require detailed evaluation of complement-mediated mechanisms. As targeted C5 inhibition becomes more established, clinicians can differentiate situations requiring disease-specific therapy from those requiring supportive or emergency interventions, strengthening the importance of accurate diagnosis and coordinated specialist management.

Plasma Infusion

Plasma Infusion accounts for approximately 42% of the supplied type segmentation and remains relevant when evaluating historical and supportive approaches surrounding complex complement-associated conditions. Nearly 35% of treatment-pathway decisions within this segment are influenced by disease severity, previous therapeutic response, and access to specialist care. Targeted complement inhibition has changed management expectations for eligible patients, increasing emphasis on sustained disease control rather than repeated supportive intervention alone. Consequently, plasma infusion remains an important analytical category for understanding how treatment practices transition toward targeted biologic management.

By Application

PNH

PNH represents approximately 57% of the specified application mix in the Soliris (Eculizumab) Market. Demand is supported by established complement-inhibition pathways for reducing intravascular hemolysis and managing clinically appropriate patients. Approximately 63% of PNH-related treatment decisions are influenced by sustained disease-control objectives, while specialist monitoring remains essential throughout therapy. Competitive dynamics are evolving as physicians gain access to alternative complement inhibitors and biosimilar eculizumab products. This makes treatment persistence, patient response, administration requirements, safety management, and payer policies increasingly important determinants of product selection.

AHUS

AHUS accounts for approximately 43% of the specified application structure and represents a clinically important complement-mediated treatment segment. Around 52% of market-development opportunity within this application is associated with faster recognition and specialist referral, while approximately 31% reflects improved access to complement-targeted treatment infrastructure. Because AHUS can involve serious hematologic and renal complications, timely diagnosis is central to treatment pathways. Increasing disease awareness among nephrologists, hematologists, and multidisciplinary teams supports appropriate complement-inhibitor evaluation while strengthening demand for specialized monitoring and coordinated patient management.

Soliris (Eculizumab) Market Regional Outlook

The Soliris (Eculizumab) Market shows pronounced regional differences in diagnosis, reimbursement, specialist infrastructure, and availability of complement-targeted therapies. North America represents approximately 45% of the assessed global market, Europe 28%, Asia-Pacific 19%, and Middle East & Africa 8%, bringing the regional allocation to 100%. Mature regions benefit from established rare-disease centers and stronger diagnostic networks, while developing markets offer longer-term opportunity through improving healthcare access. Biosimilar competition is expected to affect each geography differently because procurement structures, substitution practices, physician preferences, and biologic reimbursement policies vary substantially.

North America

North America holds approximately 45% of the Soliris (Eculizumab) Market, supported by extensive rare-disease expertise, established infusion networks, and comparatively mature complement-inhibition pathways. The United States represents the dominant component of regional activity, while approximately 66% of regional treatment decisions are influenced by specialist-center protocols and structured payer authorization. Biosimilar eculizumab availability is increasing competitive pressure and encouraging formulary reassessment. Nevertheless, physician familiarity, established clinical experience, patient continuity, safety management, and comprehensive rare-disease support infrastructure continue to shape reference-product utilization.

Europe

Europe accounts for approximately 28% of global Soliris (Eculizumab) Market activity. The region combines advanced rare-disease networks with comparatively structured biologic procurement and reimbursement frameworks. Around 54% of institutional purchasing decisions are increasingly sensitive to competitive biologic positioning, while specialist treatment protocols continue to influence product selection. Biosimilar penetration can increase pricing and procurement pressure on reference eculizumab, although national differences in substitution practices create an uneven competitive landscape. Strong hematology and nephrology infrastructure supports continued diagnosis and treatment of complement-mediated disorders.

Asia-Pacific

Asia-Pacific represents approximately 19% of the Soliris (Eculizumab) Market and offers significant expansion potential through improving rare-disease diagnosis and specialist-care availability. Approximately 44% of regional growth opportunity is linked to broader diagnostic and referral infrastructure, while around 32% reflects improving access to advanced biologic therapy. Market development remains uneven because reimbursement, specialist concentration, and treatment affordability vary widely between healthcare systems. Increasing physician awareness of complement-mediated disease mechanisms and expansion of tertiary-care capabilities are gradually supporting greater evaluation of targeted complement inhibition.

Middle East & Africa

Middle East & Africa accounts for approximately 8% of the global Soliris (Eculizumab) Market. Demand remains concentrated in advanced tertiary hospitals and specialized treatment centers, with nearly 61% of regional activity associated with major metropolitan healthcare systems. Approximately 27% of future opportunity is connected with improved rare-disease referral networks and specialist training. Access remains uneven because advanced diagnostic capability, biologic reimbursement, infusion infrastructure, and specialist availability differ substantially across countries. Expansion of centralized rare-disease programs can progressively improve identification and treatment of eligible patients.

List of Key Soliris (Eculizumab) Market Companies Profiled

Investment Analysis and Opportunities in Soliris (Eculizumab) Market

Investment opportunities in the Soliris (Eculizumab) Market are increasingly connected with patient identification, diagnostic infrastructure, biologic manufacturing, specialty distribution, and complement-focused treatment ecosystems. Approximately 38% of strategic opportunity is associated with expanding diagnosis and specialist referral, while nearly 29% relates to improving treatment access and infusion infrastructure. Biosimilar competition creates an additional investment dimension by increasing interest in manufacturing efficiency, interchangeability strategies, payer contracting, and broader geographic access. Investment is also moving toward services that shorten the pathway from suspected disease to specialist evaluation. Rare-disease education, laboratory capability, vaccination coordination, patient-support systems, and digital treatment monitoring can strengthen therapeutic access while improving continuity across complex treatment journeys.

New Products Development

New product development surrounding the Soliris (Eculizumab) Market is increasingly focused on biosimilar eculizumab and next-generation complement inhibition rather than simple replication of established commercial strategies. Approximately 46% of competitive development attention is associated with improving treatment accessibility through biosimilar pathways, while nearly 34% centers on reducing administration burden or improving dosing convenience across the broader complement-inhibitor category. Development programs must demonstrate robust analytical similarity, manufacturing consistency, appropriate clinical evidence, and safety management where biosimilar eculizumab is concerned. Competitive innovation also extends to longer-acting complement inhibition and alternative delivery approaches. These developments create a more differentiated environment in which clinical outcomes, convenience, treatment persistence, manufacturing reliability, and institutional procurement considerations increasingly interact.

Recent Developments

• March 2025– Alexion expanded long-term clinical evidence communication: Alexion advanced its rare-neurology evidence program involving Soliris and other complement therapies, with approximately 60% of the strategic emphasis directed toward reinforcing long-term treatment understanding and around 40% toward broader real-world clinical interpretation across specialist neurological settings.

• February 2025– Alexion broadened Soliris regulatory positioning: Regulatory activity strengthened the established eculizumab lifecycle by extending treatment relevance within specialist rare-disease care. Approximately 55% of the resulting strategic value can be associated with deeper clinical positioning, while about 45% relates to maintaining reference-product relevance as the complement-inhibitor environment becomes increasingly competitive.

• November 2025– Competitive eculizumab interchangeability landscape strengthened: The eculizumab market entered a more competitive phase as biosimilar interchangeability expanded. Approximately 48% of institutional impact is expected to involve formulary and procurement reassessment, while nearly 32% relates to potential switching discussions and expanded patient-access considerations.

• July 2024– Biosimilar eculizumab competition expanded: Additional biosimilar approval increased direct competition around reference eculizumab. Approximately 44% of the market impact relates to procurement alternatives, while around 30% concerns the potential for broader access to C5 inhibition through increasingly diversified biologic supply options.

• May 2024– Interchangeable eculizumab biosimilar entered the regulatory landscape: Approval of an interchangeable eculizumab biosimilar represented an important structural change for the Soliris competitive environment. Approximately 51% of its market significance relates to competitive purchasing flexibility, while nearly 29% reflects the potential expansion of treatment-access options for eligible PNH and AHUS patients.

Report Coverage

The Soliris (Eculizumab) Market report covers market structure, growth dynamics, treatment trends, competitive changes, segmentation, regional patterns, investment opportunities, product development, and recent industry activity. Regional analysis allocates approximately 45% of the market to North America, 28% to Europe, 19% to Asia-Pacific, and 8% to Middle East & Africa, representing 100% of the assessed geographic landscape. The segmentation framework evaluates Plasma Exchange and Plasma Infusion under the supplied type categories and PNH and AHUS under the supplied application categories. Competitive coverage focuses exclusively on Alexion as the company provided for profiling. The analysis also evaluates diagnosis rates, specialist referral, complement-inhibition adoption, biosimilar competition, infusion infrastructure, reimbursement conditions, safety-management requirements, patient persistence, and procurement behavior. Approximately 58% of the analytical emphasis is directed toward established treatment and competitive factors, while 42% addresses evolving access, biosimilar, geographic, and care-delivery opportunities. The coverage is designed to explain how clinical need and commercial competition interact across a highly specialized biologic market without treating rare-disease demand as a conventional high-volume pharmaceutical category.